Systemic Antifungal Prophylaxis in Patients ...
Document type :
Article dans une revue scientifique
PMID :
Permalink :
Title :
Systemic Antifungal Prophylaxis in Patients Hospitalized in Hematology Units in France: The AFHEM Cross-Sectional Observational Study.
Author(s) :
Gangneux, Jean-Pierre [Auteur]
El-Cheikh, Jean [Auteur]
Herbrecht, Raoul [Auteur]
Yakoub-Agha, Ibrahim [Auteur]
Lille Inflammation Research International Center - U 995 [LIRIC]
Quiniou, Jean-Baptiste [Auteur]
Caillot, Denis [Auteur]
Michallet, Mauricette [Auteur]
El-Cheikh, Jean [Auteur]
Herbrecht, Raoul [Auteur]
Yakoub-Agha, Ibrahim [Auteur]
Lille Inflammation Research International Center - U 995 [LIRIC]
Quiniou, Jean-Baptiste [Auteur]
Caillot, Denis [Auteur]
Michallet, Mauricette [Auteur]
Journal title :
Infectious Diseases and Therapy
Abbreviated title :
Infect Dis Ther
Volume number :
7
Pages :
309–325
Publication date :
2018-09
Keyword(s) :
Invasive fungal disease
Hematology
Antifungal prophylaxis
Systemic antifungal treatment
Hematology
Antifungal prophylaxis
Systemic antifungal treatment
HAL domain(s) :
Sciences du Vivant [q-bio]
English abstract : [en]
Introduction: The frequency of invasive fungal diseases (IFDs) has increased in recent years. Within a context where both treatments and guidelines are fast evolving, we aim to shed new light on IFD management in hematologic ...
Show more >Introduction: The frequency of invasive fungal diseases (IFDs) has increased in recent years. Within a context where both treatments and guidelines are fast evolving, we aim to shed new light on IFD management in hematologic departments in France. Methods: A multicenter cross-sectional observational study was prospectively conducted in 24 French centers in September and October 2013. Results: Four hundred ninety-four hospitalized children and adult patients suffering from hematologic malignancy were enrolled: 147 (30%) were allogeneic hematopoietic stem cell transplant (HSCT) recipients, 131 (27%) were patients with acute myeloblastic leukemia or myelodysplastic syndrome (MDS), 71 (14%) were patients with acute lymphoblastic leukemia who did not undergo allogeneic HSCT, and the 145 (29%) remaining patients did not belong to the three above groups. Two hundred forty-six patients (50%) received antifungal treatment, which was prophylactic in 187 (76%) treated patients. These rates were similar across all groups (63–80%). Patients received prophylaxis with an azole (79%), intravenous amphotericin B formulation (10%), echinocandin (9%), or two combination drugs (2%). Conclusion: Results indicate that prophylaxis is the leading antifungal strategy in French hematology units, regardless of the disease condition, representing 76% of prescriptions for antifungal therapy.Show less >
Show more >Introduction: The frequency of invasive fungal diseases (IFDs) has increased in recent years. Within a context where both treatments and guidelines are fast evolving, we aim to shed new light on IFD management in hematologic departments in France. Methods: A multicenter cross-sectional observational study was prospectively conducted in 24 French centers in September and October 2013. Results: Four hundred ninety-four hospitalized children and adult patients suffering from hematologic malignancy were enrolled: 147 (30%) were allogeneic hematopoietic stem cell transplant (HSCT) recipients, 131 (27%) were patients with acute myeloblastic leukemia or myelodysplastic syndrome (MDS), 71 (14%) were patients with acute lymphoblastic leukemia who did not undergo allogeneic HSCT, and the 145 (29%) remaining patients did not belong to the three above groups. Two hundred forty-six patients (50%) received antifungal treatment, which was prophylactic in 187 (76%) treated patients. These rates were similar across all groups (63–80%). Patients received prophylaxis with an azole (79%), intravenous amphotericin B formulation (10%), echinocandin (9%), or two combination drugs (2%). Conclusion: Results indicate that prophylaxis is the leading antifungal strategy in French hematology units, regardless of the disease condition, representing 76% of prescriptions for antifungal therapy.Show less >
Language :
Anglais
Audience :
Internationale
Popular science :
Non
Administrative institution(s) :
Inserm
Université de Lille
CHU Lille
Université de Lille
CHU Lille
Research team(s) :
Immunity, inflammation and fibrsis in auto and allo-reactivity
Submission date :
2019-03-01T14:34:36Z
2023-12-21T12:44:23Z
2023-12-21T12:44:23Z
Files
- s40121-018-0203-4.pdf
- Non spécifié
- Open access
- Access the document
Except where otherwise noted, this item's license is described as Attribution-NonCommercial 3.0 United States